A multicenter Phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients
Open Access
- 18 January 2025
- journal article
- research article
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110241
Abstract
No abstract availableKeywords
Funding Information
- UCB
This publication has 22 references indexed in Scilit:
- Seizure Rescue Therapies: Comparing Approved and Commonly Used Benzodiazepine FormulationsNeurotherapeutics, 2023
- The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and BeyondCNS Drugs, 2021
- Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy PatientsCNS Drugs, 2020
- The ‘Photosensitivity Model’ is (also) a model for focal (partial) seizuresEpilepsy Research, 2017
- Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and BeyondCNS Drugs, 2016
- Single dose efficacy evaluation of two partial benzodiazepine receptor agonists in photosensitive epilepsy patients: A placebo-controlled pilot studyEpilepsy Research, 2016
- How predictive are photosensitive epilepsy models as proof of principle trials for epilepsy?Seizure: European Journal of Epilepsy, 2014
- Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsyEuropean Journal of Pharmacology, 2009
- Seletracetam (UCB 44212)Neurotherapeutics, 2007
- Photosensitivity as a model for acute antiepileptic drug studiesElectroencephalography and Clinical Neurophysiology, 1986